Edward Albini
Director of Finance/CFO chez SUTRO BIOPHARMA, INC.
Fortune : 603 098 $ au 31/03/2024
Profil
Edward C.
Albini is currently the Chief Financial Officer & Secretary at Sutro Biopharma, Inc. He previously worked as the Director-Finance & International Operations at Genentech, Inc. and as the Chief Financial Officer at Lynx Therapeutics, Inc., Carbylan Therapeutics, Inc., Itero Biopharmaceuticals, Inc., Novacea, Inc., and Itero Holdings LLC.
Albini received his undergraduate degree from Santa Clara University and his MBA from Haas School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SUTRO BIOPHARMA, INC.
0,17% | 05/03/2024 | 106 743 ( 0,17% ) | 603 098 $ | 31/03/2024 |
Postes actifs de Edward Albini
| Sociétés | Poste | Début |
|---|---|---|
| SUTRO BIOPHARMA, INC. | Director of Finance/CFO | 31/01/2013 |
Anciens postes connus de Edward Albini
| Sociétés | Poste | Fin |
|---|---|---|
Itero Holdings LLC
 Itero Holdings LLC Financial ConglomeratesFinance Itero Holdings LLC provides investment services. The private company is based in San Jose, CA. | Director of Finance/CFO | 01/01/2016 |
Itero Biopharmaceuticals, Inc.
 Itero Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Itero Biopharmaceuticals, Inc. develops biopharmaceutical products for novel therapeutic proteins and antibodies. The firm focuses on the development and commercialization of protein therapeutics that offer significant clinical and commercial advantages over marketed alternatives. It provides recombinant follicle stimulating hormone for the treatment of female infertility. The company was founded in 2006 by Dr. V. Bryan Lawlis Jr., Dr. Darlene P. Horton and Roy Jerald Beers and is headquartered in Mountain View, CA. | Director of Finance/CFO | 01/01/2011 |
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Director of Finance/CFO | 01/01/2009 |
Lynx Therapeutics, Inc.
 Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Lynx Therapeutics, Inc. was a developer of genetic analysis products for the pharmaceutical, biotechnology and agriculture industries. It's MPSSTM instruments analyze millions of DNA molecules in parallel enabling genome structure characterization at an unprecedented level of resolution. MPSSTM provides comprehensive and quantitative digital information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. The company was headquartered in Hayward, CA. | Director of Finance/CFO | 01/02/2004 |
Carbylan Therapeutics, Inc.
 Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA. | Director of Finance/CFO | - |
Formation de Edward Albini
| Santa Clara University | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SUTRO BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Lynx Therapeutics, Inc.
Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Lynx Therapeutics, Inc. was a developer of genetic analysis products for the pharmaceutical, biotechnology and agriculture industries. It's MPSSTM instruments analyze millions of DNA molecules in parallel enabling genome structure characterization at an unprecedented level of resolution. MPSSTM provides comprehensive and quantitative digital information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. The company was headquartered in Hayward, CA. | Health Technology |
Carbylan Therapeutics, Inc.
Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA. | Health Technology |
Itero Biopharmaceuticals, Inc.
Itero Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Itero Biopharmaceuticals, Inc. develops biopharmaceutical products for novel therapeutic proteins and antibodies. The firm focuses on the development and commercialization of protein therapeutics that offer significant clinical and commercial advantages over marketed alternatives. It provides recombinant follicle stimulating hormone for the treatment of female infertility. The company was founded in 2006 by Dr. V. Bryan Lawlis Jr., Dr. Darlene P. Horton and Roy Jerald Beers and is headquartered in Mountain View, CA. | Health Technology |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Itero Holdings LLC
Itero Holdings LLC Financial ConglomeratesFinance Itero Holdings LLC provides investment services. The private company is based in San Jose, CA. | Finance |
